UPDATE - Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting
03 mai 2022 14h13 HE
|
Passage Bio
PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting
02 mai 2022 16h01 HE
|
Passage Bio
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
22 avr. 2022 16h01 HE
|
Passage Bio
PHILADELPHIA, April 22, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease
29 mars 2022 07h00 HE
|
Passage Bio
Preclinical studies conducted with University of Pennsylvania’s Gene Therapy Program demonstrate biologic effects of vector-optimized gene therapy PBKR03 for Krabbe diseasePBKR03 showed marked...
Passage Bio to Participate in Upcoming Investor Conferences
28 mars 2022 07h00 HE
|
Passage Bio
PHILADELPHIA, March 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway
15 mars 2022 07h00 HE
|
Passage Bio
Company to reduce workforce and prioritize research and development programs to reduce operating expensesContinued focus on execution of three ongoing clinical trials for GM1 gangliosidosis, Krabbe...
Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition
10 mars 2022 07h00 HE
|
Passage Bio
PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
03 mars 2022 07h00 HE
|
Passage Bio
Presented positive interim biomarker, safety and efficacy data, including gains in developmental milestones, for Cohort 1 patients in Imagine-1 clinical trial for GM1 gangliosidosisDosed first...
Passage Bio to Participate in Upcoming March Investor Conferences
01 mars 2022 07h00 HE
|
Passage Bio
PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022
24 févr. 2022 07h00 HE
|
Passage Bio
PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...